Federal Contractor Profile
Iit Research Institute
$56M obligated·101 awards·2 agencies·12 NAICS
Federal Contracts
Showing award actions 51–100 of 141 funded award actions, most recent first.
- Contracts with positive obligations
- 101
- Funded award actions shown
- 141
- Obligations shown
- $56M
- Awarding agencies
- 2
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of September 28, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Apr 26, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $207K |
| Mar 29, 2022 | Department of Health and Human ServicesNIH NCI | 75N91022C00010 | 541715 | PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS | $75K |
| Mar 28, 2022 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER | $291K |
| Feb 14, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $10K |
| Dec 10, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022F00001 | 541714 | PRECLINICAL MICROBIOLOGICAL, SAFETY, TOXICOLOGY, AND PHARMACOKINETIC SERVICES | $1.9M |
| Dec 3, 2021 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $34K |
| Sep 30, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP) | $11 |
| Sep 29, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95021F00001 | 541715 | CONTRACT KICK-OFF MEETING FOR NINDS PHARMACOLOGY AND TOXICOLOGY FOR THERAPEUTICS PROGRAM (PTTP) | $2K |
| Sep 7, 2021 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $702K |
| Aug 23, 2021 | Department of Health and Human ServicesNIH NCI | 75N91021F00001 | 541714 | EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER | $535K |
| Jul 19, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $1.3M |
| Jun 23, 2021 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $25K |
| Apr 27, 2021 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $118K |
| Feb 26, 2021 | Department of Health and Human ServicesNIH NCI | HHSN26100003 | 541690 | IGF::OT::IGF NEXT PRECLINICAL TOXICOLOGY&PHARMACOLOGY OF DRUGS DEVELOPED FOR CANCER PATIENTS, TO#3, EXPLORATORY STUDIES OF CCR4 CART CELLS | $239K |
| Feb 11, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $530K |
| Nov 30, 2020 | Department of DefenseW6QK ACC-APG NATICK | W911QY21C0014 | 541380 | TECHNLOLOGY TRANSFER ASSAYS | $981K |
| Sep 24, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00003 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF DRINABANT, A CANNABINOID RECEPTOR (CB-1) ANTAGONIST, FOR ACUTE CANNABINOID OVERDOSE (ACO). POP: 09/25/2020 TO 03/24/2021. | $324K |
| Sep 21, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541690 | SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG DEVELOPMENT) POP 09/23/2020-09/22/2021. | $589K |
| Sep 16, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00002 | 541714 | COVID-19 RELATED STUDY INVOLVING DOGS | $598K |
| Sep 16, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00002 | 541712 | TASK ORDER TITLE: NON-CLINICAL SAFETY OF MITRAGYNINE TO SUPPORT ITS FUTURE ORAL THERAPY FOR ANALGESIA INDICATION. POP: 09/17/2020 TO 03/16/2022. | $1.8M |
| Sep 15, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95020F00001 | 541712 | NON-CLINICAL SAFETY OF PTH-1A, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE. POP: 09/16/2020 TO 03/15/2020. | $153K |
| Sep 14, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTION PERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022 | $213K |
| Sep 2, 2020 | Department of Health and Human ServicesNIH NCI | 75N91020F00001 | 541714 | PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER | $430K |
| Aug 27, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00091 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $7K |
| Aug 26, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | HHSN27100001 | 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | $95K |
| Jul 17, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00091 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $81K |
| Jun 3, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00090 | 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | $85K |
| Apr 14, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118F33001 | 541711 | IGF::OT::IGF | $637K |
| Mar 3, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO10033002T | 325414 | IGF::OT::IGF | $84K |
| Feb 25, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00090 | 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | $24K |
| Aug 27, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00090 | 541712 | GLP 28 DAY TOXICITY STUDY OF ACT-1 WHEN APPLIED TOPICALLY TO EYES TWICE DAILY FOR 28 DAYS IN DOGS WITH A 14 DAY RECOVERY PERIOD. POP: 09/01/2019 TO 02/29/2020. | $441K |
| Aug 26, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95019F00091 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF ACOZIBOROLE (SCYX-7158) TO SUPPORT HUMAN AFRICAN TRYPANOSOMIASIS (HAT OR "SLEEPING SICKNESS"). POP: 09/01/2019 TO 08/31/2020. | $1.1M |
| Aug 6, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118F33002 | 541711 | IGF::OT::IGF | $726K |
| Mar 29, 2019 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | HHSN27100001 | 541712 | IGF::OT::IGF TASK ORDER AWARD FOR "NON-CLINICAL SAFETY ASSESSMENT OF SPIF TO SUPPORT CHRONIC GVHD INDICATION" TO IIT RESEARCH INSTITUTE | $194K |
| Mar 21, 2019 | Department of Health and Human ServicesNIH NCI | 75N91018F00004 | 541690 | THREE RABBIT STUDY: (1) DOSE RANGE FINDING STUDY IN RABBITS VIA ORAL GAVAGE (NON-GLP); (2) PRELIMINARY EMBRYO FETAL DEVELOPMENTAL STUDY IN RABBITS VIA ORAL GAVAGE (NON-GLP); (3) EMBRYO FETAL DEVELOPMENTAL STUDY IN NEW ZEALAND WHITE RABBITS VIA ORAL GAVAGE (GLP)) | $52K |
| Mar 4, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118F33001 | 541711 | IGF::OT::IGF | $122K |
| Jan 25, 2019 | Department of Health and Human ServicesNIH NCI | HHSN26100004 | 541711 | IGF::OT::IGF SUPPORT FOR THE AEROSOL DEVELOPMENT OF BEXAROTENE HHSN2612015000240 TO: HHSN26100004 POP: 9/18/2017 TO 9/17/2019 | $57K |
| Jan 23, 2019 | Department of Health and Human ServicesNIH NCI | 75N91019F00129 | 541714 | "CONTRACT ORIENTATION AND KICKOFF MEETING", TASK ORDER #1 UNDER 75N91019D00012. TASK ORDER PERIOD OF PERFORMANCE: 1/25/2019-2/24/2019. | $4K |
| Jan 23, 2019 | Department of Health and Human ServicesNIH NCI | 75N91019F00129 | 541714 | "CONTRACT ORIENTATION AND KICKOFF MEETING" UNDER CONTRACT 75N91019D00013 | $4K |
| Sep 25, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118F33001 | 541711 | IGF::OT::IGF | $1.8M |
| Sep 24, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50118F33002 | 541711 | IGF::OT::IGF | $1.8M |
| Sep 14, 2018 | Department of Health and Human ServicesNIH NCI | 75N91018F00005 | 541711 | IGF::OT::IGF LFA-9 (MPGES-1/5-LOX INHIBITOR): PRECLINICAL STUDIES TO SUPPORT A CLINICAL TRIAL, POP 9/17/18-9/16/2020 (UP TO 9/17/2021 IF ALL OPTIONAL TASKS EXERCISED) | $686K |
| Sep 11, 2018 | Department of Health and Human ServicesNIH NCI | 75N91018F00003 | 541711 | PRECLINICAL EFFICACY EVALUATION OF THE LIPID-BASED SMEDDS FORMULATION OF DIM, BR-9001, TO AWARD 3 | $119K |
| Sep 5, 2018 | Department of Health and Human ServicesNIH NCI | 75N91018F00004 | 541690 | THREE RABBIT STUDY: (1) DOSE RANGE FINDING STUDY IN RABBITS VIA ORAL GAVAGE (NON-GLP); (2) PRELIMINARY EMBRYO FETAL DEVELOPMENTAL STUDY IN RABBITS VIA ORAL GAVAGE (NON-GLP); (3) EMBRYO FETAL DEVELOPMENTAL STUDY IN NEW ZEALAND WHITE RABBITS VIA ORAL GAVAGE (GLP)) | $436K |
| Aug 30, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95018F00005 | 541712 | NON-CLINICAL SAFETY ASSESSMENT OF BPN14770 TO SUPPORT PEDIATRIC POPULATION WITH FRAGILE X SYNDROME | $902K |
| Aug 21, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95018F00004 | 541712 | IIT RESEARCH INSTITUTE:1107221 | $1.2M |
| Aug 7, 2018 | Department of Health and Human ServicesNIH NCI | 75N91018F00003 | 541711 | PRECLINICAL EFFICACY EVALUATION OF THE LIPID-BASED SMEDDS FORMULATION OF DIM, BR-9001, TO AWARD 3 | $855K |
| Jul 11, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 75N95018F00003 | 541712 | IIT RESCH INSTITUTE:1107221 [18-005715] TO PERFORM THE STUDY "SINGLE PO DOSE CARDIOVASCULAR AND PULMONARY SAFETY PHARMACOLOGY STUDY OF METARRESTIN IN TELEMETERED BEAGLE DOGS USING LATIN-SQUARE CROSS OVER STUDY DESIGN". | $139K |
| Jun 26, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | HHSO10033004T | 325414 | IGF::OT::IGF | $44K |
| Jun 4, 2018 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93018F00001 | 541714 | TO ISSUE TASK ORDER HHSN27200001, TASK AREA F, BASE IDIQ CONTRACT KICK-OFF | $26K |
Get Alerted Before Iit Research Institute's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free